Werner Kroll - Quidel Senior Development
| QDEL Stock | USD 34.78 0.11 0.32% |
Executive
Dr. Werner Kroll serves as Senior Vice President, RD of the Company. Prior to joining us, Dr. Kroll was Vice President and Global Head Research and Innovation for Novartis Molecular since 2009. Prior to holding that position, he held a variety of senior positions from 2005 to 2009 at Novartis. Dr. Kroll has also held senior positions at Bayer from 1991 to 2005 since 2014.
| Age | 68 |
| Tenure | 11 years |
| Professional Marks | Ph.D |
| Address | 9975 Summers Ridge Road, San Diego, CA, United States, 92121 |
| Phone | 858 552 1100 |
| Web | https://www.quidelortho.com |
Werner Kroll Latest Insider Activity
Tracking and analyzing the buying and selling activities of Werner Kroll against Quidel stock is an integral part of due diligence when investing in Quidel. Werner Kroll insider activity provides valuable insight into whether Quidel is net buyers or sellers over its current business cycle. Note, Quidel insiders must abide by specific rules, including filing SEC forms every time they buy or sell Quidel'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Werner Kroll over six months ago Disposition of 1170 shares by Werner Kroll of Quidel subject to Rule 16b-3 | ||
Werner Kroll over a year ago Acquisition by Werner Kroll of 11433 shares of Quidel subject to Rule 16b-3 | ||
Werner Kroll over a year ago Acquisition by Werner Kroll of 2743 shares of Quidel subject to Rule 16b-3 | ||
Werner Kroll over a year ago Acquisition by Werner Kroll of 25 shares of Quidel subject to Rule 16b-3 |
Quidel Management Efficiency
Return On Capital Employed is expected to rise to 0.02 this year, although the value of Return On Tangible Assets will most likely fall to (0). At this time, Quidel's Intangible Assets are quite stable compared to the past year. Other Assets is expected to rise to about 477.9 M this year, although the value of Deferred Long Term Asset Charges will most likely fall to about 25.7 M. Quidel's management efficiency ratios could be used to measure how well Quidel manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Marcee Maroney | Pulmonx Corp | 55 | |
| Katie Keller | Neuropace | N/A | |
| Elizabeth Gasser | Tandem Diabetes Care | 49 | |
| Justin Ward | Bruker | N/A | |
| Leah Akin | Neuropace | N/A | |
| Jeff Bertolini | Si Bone | N/A | |
| Aimee Einstein | Si Bone | N/A | |
| Alex CMA | LivaNova PLC | 55 | |
| Sarah Oliker | CONMED | 43 | |
| Brent Lalomia | CONMED | 49 | |
| Irina Ridley | Neuropace | 38 | |
| Dan Manea | Insulet | 57 | |
| Deborah CPA | Insulet | 53 | |
| Trui Hebbelinck | LivaNova PLC | 52 | |
| Jordan MD | Tandem Diabetes Care | N/A | |
| Joel Batts | Orthopediatrics Corp | N/A | |
| Richard Glaze | CONMED | 59 | |
| Andreas Henke | Inspire Medical Systems | N/A | |
| Anthony Recupero | Si Bone | 66 | |
| Catherine Szyman | Masimo | 58 | |
| Shannon Hansen | Tandem Diabetes Care | 58 | |
Management Performance
| Return On Equity | -0.51 | ||||
| Return On Asset | 0.0065 |
Quidel Leadership Team
Elected by the shareholders, the Quidel's board of directors comprises two types of representatives: Quidel inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Quidel. The board's role is to monitor Quidel's management team and ensure that shareholders' interests are well served. Quidel's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Quidel's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Ruben Argueta, Director Relations | ||
| Juliet Cunningham, Vice Relations | ||
| Michelle JD, Chief Officer | ||
| Chockalingam Palaniappan, Chief Officer | ||
| Joseph CPA, Chief Officer | ||
| Louise Brandy, Senior Officer | ||
| Tamara Ranalli, Molecular Leader | ||
| Phillip Askim, Associate VP | ||
| Patrick Klein, Senior Officer | ||
| Ronald Bowman, Chief Officer | ||
| William Ferenczy, Point Leader | ||
| Jonathan Siegrist, Executive CTO | ||
| Philip McLellan, Chief Officer | ||
| Douglas Bryant, CEO and President and Director | ||
| Brian Blaser, CEO President | ||
| Werner Kroll, Senior Development | ||
| Lisa Hayes, Vice Communications | ||
| Robert JD, Executive President | ||
| Michelle Hodges, General VP | ||
| Michael Iskra, Executive Officer |
Quidel Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Quidel a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.51 | ||||
| Return On Asset | 0.0065 | ||||
| Profit Margin | (0.74) % | ||||
| Operating Margin | 0.07 % | ||||
| Current Valuation | 4.94 B | ||||
| Shares Outstanding | 67.45 M | ||||
| Shares Owned By Insiders | 1.40 % | ||||
| Shares Owned By Institutions | 98.60 % | ||||
| Number Of Shares Shorted | 4.35 M | ||||
| Price To Earning | 5.56 X |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Quidel. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in income. For more information on how to buy Quidel Stock please use our How to buy in Quidel Stock guide.You can also try the Latest Portfolios module to quick portfolio dashboard that showcases your latest portfolios.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Quidel. If investors know Quidel will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Quidel listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.77) | Earnings Share (30.54) | Revenue Per Share | Quarterly Revenue Growth (0.05) | Return On Assets |
The market value of Quidel is measured differently than its book value, which is the value of Quidel that is recorded on the company's balance sheet. Investors also form their own opinion of Quidel's value that differs from its market value or its book value, called intrinsic value, which is Quidel's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Quidel's market value can be influenced by many factors that don't directly affect Quidel's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Quidel's value and its price as these two are different measures arrived at by different means. Investors typically determine if Quidel is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Quidel's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.